Additional file 1: Table S1. of Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Univariable logistic and Cox regression analyses for RR, PFS, and OS. Table S2. Univariable and multivariable logistic and Cox regression analyses of risk factors associated with RR, PFS, and OS. Note ‘Pretherapy NLR’ is grouped by its median of 3.2. Table S3. Univariable and multivariable logistic and Cox regression analyses of risk factors associated with RR, PFS, and OS. Note ‘Pretherapy NLR’ is considered as a continuous variable. Table S4. Univariable and multivariable Cox regression analyses of risk factors associated with PFS. Note that two variables ‘Duration of prior anti-VEGF Therapies’ and ‘Pretherapy NLR (with the cutoff value of 3)’ are combined. Table S5. Univariable and multivariable Cox regression analyses of risk factors associated with PFS. Note that two variables ‘Duration of prior anti-VEGF Therapies’ and ‘Pretherapy NLR (with the cutoff value of 3.2 [median])’ are combined. Figure S1. The boxplot of pretherapy NLR by the duration of prior anti-VEGF therapies. The p-value is calculated using the Kruskal. (DOCX 38 kb)